ecancer

First- and second-line treatments for locally advanced renal cell carcinoma

Prof Jorge A. Garcia - Cleveland Clinic, Cleveland, USA

8 May 2019

Highlights from IGILUC 2019

Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt

8 May 2019

Quality of life and local treatment of oligometastatic prostate cancer

Prof Claude Abbou - Clinique de l'Alma, Paris, France

8 May 2019

Challenges in the treatment of upper urinary tract tumours

Prof Amr Emara - Basingstoke and North Hampshire Hospital, Basingstoke, UK

8 May 2019

PARP inhibitors and their side effects in solid tumour therapy

Paula Anastasia - David Geffen School of Medicine at UCLA Los Angeles, USA

8 May 2019

Challenges to Jordanian Muslim men with prostate cancer

Abdulmalik Hasanain - Victoria University of Wellington, Wellington, New Zealand

8 May 2019

5' UTR mutations in prostate cancer

Dr Yiting Lim, Fred Hutchinson Cancer Research Center, Seattle, USA

15 Apr 2019

Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies

Dr James Gulley - National Cancer Institute, Bethesda, USA

15 Apr 2019

Risk factors for prostate cancer in men of African descent

Dr Faruk Mohammed - Ahmadu Bello University, Zaria, Nigeria

15 Apr 2019

Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer

Dr Sumit Subudhi - MD Anderson Cancer Center, Houston, USA

19 Feb 2019

KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma

Prof David McDermott - Beth Israel Deaconess Medical Center, Boston, USA

19 Feb 2019

Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma

Dr Stefanie Fischer - The Christie NHS Foundation Trust, Manchester, UK

19 Feb 2019

More from ecancer